Cargando…
Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity
LAYMAN SUMMARY: HER2 is an oncogenic driver in a subset of breast cancer. Despite the fact that there are the options of several anti-HER2 targeted therapies, most patients with metastatic HER2+ breast cancer die from the disease. Therapies to overcome treatment resistance in the metastatic settings...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224522/ https://www.ncbi.nlm.nih.gov/pubmed/35742993 http://dx.doi.org/10.3390/ijms23126547 |